Among the most innovative modern advancements for treating obstructive sleep apnea are advanced hypoglossal nerve stimulation systems—such as the FDA-approved Nyxoah Genio system—which provide bilateral, leadless, and battery-free internal neurostimulation controlled by wearable technology. Additionally, novel pharmacological approaches involving GLP-1 receptor agonist weight-loss medications have shown remarkable clinical efficacy in reducing apnea severity by decreasing upper airway soft tissue crowding, offering patients non-surgical alternatives alongside traditional positive airway pressure devices.